Suppr超能文献

利用新型 NF-κB/NFAT 报告细胞平台进行嵌合抗原受体文库筛选。

Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.

机构信息

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.

出版信息

Mol Ther. 2019 Feb 6;27(2):287-299. doi: 10.1016/j.ymthe.2018.11.015. Epub 2018 Nov 20.

Abstract

Chimeric antigen receptor (CAR)-T cell immunotherapy is under intense preclinical and clinical investigation, and it involves a rapidly increasing portfolio of novel target antigens and CAR designs. We established a platform that enables rapid and high-throughput CAR-screening campaigns with reporter cells derived from the T cell lymphoma line Jurkat. Reporter cells were equipped with nuclear factor κB (NF-κB) and nuclear factor of activated T cells (NFAT) reporter genes that generate a duplex output of enhanced CFP (ECFP) and EGFP, respectively. As a proof of concept, we modified reporter cells with CD19-specific and ROR1-specific CARs, and we detected high-level reporter signals that allowed distinguishing functional from non-functional CAR constructs. The reporter data were highly reproducible, and the time required for completing each testing campaign was substantially shorter with reporter cells (6 days) compared to primary CAR-T cells (21 days). We challenged the reporter platform to a large-scale screening campaign on a ROR1-CAR library, and we showed that reporter cells retrieved a functional CAR variant that was present with a frequency of only 6 in 1.05 × 10. The data illustrate the potential to implement this reporter platform into the preclinical development path of novel CAR-T cell products and to inform and accelerate the selection of lead CAR candidates for clinical translation.

摘要

嵌合抗原受体 (CAR)-T 细胞免疫疗法正在进行深入的临床前和临床研究,涉及到越来越多的新型靶抗原和 CAR 设计。我们建立了一个平台,该平台使用源自 T 细胞淋巴瘤系 Jurkat 的报告细胞,能够快速且高通量地进行 CAR 筛选实验。报告细胞配备了核因子 κB (NF-κB) 和活化 T 细胞核因子 (NFAT) 报告基因,分别产生增强型 CFP (ECFP) 和 EGFP 的双输出。作为概念验证,我们用 CD19 特异性和 ROR1 特异性 CAR 对报告细胞进行了修饰,并检测到高水平的报告信号,允许区分功能性和非功能性 CAR 构建体。报告数据高度可重现,与使用原代 CAR-T 细胞 (21 天) 相比,使用报告细胞完成每次测试实验的时间大大缩短 (6 天)。我们在 ROR1-CAR 文库中对报告平台进行了大规模筛选实验,并表明报告细胞检索到了一个功能型 CAR 变体,其频率仅为 1.05×10 的 6 次方。这些数据说明了将该报告平台应用于新型 CAR-T 细胞产品的临床前开发路径的潜力,并为临床转化的 CAR 候选物的选择提供信息和加速。

相似文献

引用本文的文献

3
Effectors of the Future: Universal Chimeric Antigen Receptor.未来的效应器:通用嵌合抗原受体
Transfus Med Hemother. 2024 Jul 15;52(1):61-76. doi: 10.1159/000539609. eCollection 2025 Feb.
7

本文引用的文献

8
A cellular platform for the evaluation of immune checkpoint molecules.用于评估免疫检查点分子的细胞平台。
Oncotarget. 2017 May 4;8(39):64892-64906. doi: 10.18632/oncotarget.17615. eCollection 2017 Sep 12.
10
Phenotypic screening-the fast track to novel antibody discovery.表型筛选——发现新型抗体的快速通道。
Drug Discov Today Technol. 2017 Mar;23:83-90. doi: 10.1016/j.ddtec.2017.03.004. Epub 2017 Apr 25.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验